In Boston, on July 2, 2026, Vor Bio (Nasdaq: VOR), a biotech company specializing in autoimmune disease treatments, disclosed that the Compensation Committee of the Board of Directors awarded stock options for 71,200 shares of Vor Bio’s common stock and 15,150 restricted stock units (RSUs) to seven new employees on July 1, 2026. These incentives were offered to attract top talent as per Nasdaq Listing Rule 5635(c)(4) and were issued under the Vor Biopharma Inc. 2023 Inducement Plan.